Interference of o-Raffinose Cross-Linked Hemoglobin with Routine Hitachi 717 Assays

Ali, Arlene; Campbell, Janet A.

doi:10.1093/clinchem/43.9.1794

Cited by 13 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, both HBOCs and PFBOCs have been reported to interfere with certain clinical laboratory tests (e.g., serum creatinine, oximetry, coagulation tests) (98,99). When interpreting laboratory test results of patients following administration of oxygen therapeutics, appropriate corrective measures must be considered.…”

Section: Lessons From Preclinical and Clinical Studiesmentioning

confidence: 99%

Artificial Oxygen Carriers as Red Blood Cell Substitutes: A Selected Review and Current Status

2004

View full text Add to dashboard Cite

Two distinct approaches are being explored in red blood cell substitute (RCS) development: hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon-based oxygen carriers (PFBOCs). HBOCs are based on intra- and/or intermolecularly "engineered" human or animal hemoglobins (Hbs), optimized for O2 delivery and longer intravascular circulation. Some are currently being evaluated in Phase II/III clinical studies. PFBOCs are aqueous emulsions of perfluorocarbon derivatives that dissolve relatively large amounts of O2. A PFBOC based on a 60% (wt/vol) emulsion of perfluorooctyl bromide has been evaluated in Phase II/III clinical trials. Although current PFBOC products generally require patients to breathe O2 enriched air, they render certain advantages since they are totally synthetic. This article provides a short review of the basic principles, approaches, and current status of RCS development. Results of preclinical and clinical studies including recent Phase II/III clinical studies are discussed.

show abstract

Section: Lessons From Preclinical and Clinical Studiesmentioning

confidence: 99%

Artificial Oxygen Carriers as Red Blood Cell Substitutes: A Selected Review and Current Status

2004

View full text Add to dashboard Cite

show abstract

“…These samples were diluted by a factor of two or more in order to reduce the HBOC-201 level while keeping amylase levels within the linear range of detection by the Vitros 250. It should be noted that interference for other analytes such as liver enzymes was also observed with other HBOCs such as the Hemolink product, 0-raffinose crossed-linked hemoglobin [ 18]. Swine baseline levels for amylase were comparable to the human range and lipase tended to be slightly lower, probably because of differences related to lipid metabolism.…”

Section: Discussionmentioning

confidence: 86%

Amylase and Lipase Detection in Hemorrhaged Animals Treated with HBOC-201

Arnaud

McCarron

Freilich

2010

Artificial Cells, Blood Substitutes, and Biotechnology

View full text Add to dashboard Cite

HBOC-201 may alter lipase and amylase detection on chemistry analyzers using optical methods and affect pancreatic function after trauma. Amylase and lipase measurements were correlated against HBOC-201 to evaluate interference on samples spiked with 0-6g/dL HBOC-201. The detection threshold was 2.5g/dL or none when measured, respectively, on Vitros 250 or Advia 1650 instruments. Amylase and lipase from blood samples collected from 55% EBV hemorrhaged Yucatan min-pigs showed peaks around 24-48 hours. Amylase increase was not significant between treatments but lipase was higher in HBOC-201-treated animals. Animals particularly affected by the injury had elevated enzymes after hemorrhagic shock, without significant clinical consequences.

show abstract

“…Hemoglobin raffimer (Hemolink; Hemosol Inc., Toronto, Ontario, Canada) interfered with routine assays of creatinine, lactate dehydrogenase, ␥-glutamyl transferase, total bilirubin, albumin, alanine aminotransferase, and alkaline phosphatase. 26…”

Section: Hemoglobin-based Oxygen Carriersmentioning

confidence: 99%

Oxygen Therapeutics: Oxygen Delivery Without Blood

Stollings

Oyen

2006

Pharmacotherapy

View full text Add to dashboard Cite

Nearly 14 million units of packed red blood cells are transfused in the United States each year. According to the U.S. Department of Health and Human Services, in 1999, 6% of hospitals reported a shortage of blood, resulting in the cancellation or postponement of surgical procedures. The many limitations and risks of transfusions of packed red blood cells in critically ill patients have facilitated interest in developing alternative agents for oxygen delivery. Over the past few decades, safe and effective substitutes have been in development. However, no currently approved agent provides both oxygen transport and volume in place of packed red blood cells. Oxygen therapeutic products have several advantages compared with packed red blood cells, including a prolonged shelf-life, lack of a cross-matching requirement, and minimal infectious risks or concerns about immunogenicity. Hemoglobin-based oxygen carriers and perfluorocarbons are being developed. Two products are undergoing clinical trials. Polyheme is undergoing a phase III study in trauma patients, and Hemopure is being evaluated in a phase II study in patients undergoing cardiopulmonary bypass surgery. A third product (Hemolink) was being evaluated in a phase III study in patients undergoing coronary artery bypass grafting surgery; however, the trial was suspended. In addition, several other hemoglobin-based oxygen carriers are in the preclinical stages. Oxygen therapeutics have several potential clinical applications in the management of perioperative blood loss, trauma, acute normovolemic hemodilution, traumatic brain injury, and blood requirements in patients who refuse or have contraindications to transfusions of red blood cells.

show abstract

Interference of o-Raffinose Cross-Linked Hemoglobin with Routine Hitachi 717 Assays

Cited by 13 publications

References 8 publications

Artificial Oxygen Carriers as Red Blood Cell Substitutes: A Selected Review and Current Status

Artificial Oxygen Carriers as Red Blood Cell Substitutes: A Selected Review and Current Status

Amylase and Lipase Detection in Hemorrhaged Animals Treated with HBOC-201

Oxygen Therapeutics: Oxygen Delivery Without Blood

Contact Info

Product

Resources

About